Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report
Open Access
- 18 June 2021
- journal article
- case report
- Published by Wiley in Thoracic Cancer
- Vol. 12 (15) , 2214-2216
Abstract
With the increased use of immune checkpoint inhibitors (ICIs) in lung cancer, which are of great benefit to patients, more and more immune‐related adverse events (irAEs) are being reported. Checkpoint inhibitor pneumonitis (CIP) is one of the most challenging adverse events, which pose a huge challenge to clinical diagnosis and treatment, and its incidence in the real world is greatly underestimated. Currently, the treatment of CIP mainly depends on the use of glucocorticoids. As for steroid‐resistant CIP, there is no unified standardized treatment strategy. Herein, we report a case of steroid‐resistant CIP induced by pembrolizumab in a patient with advanced non‐small cell lung cancer (NSCLC), in which their symptoms were successfully controlled with pirfenidone.Keywords
This publication has 12 references indexed in Scilit:
- Moving towards personalized treatments of immune-related adverse eventsNature Reviews Clinical Oncology, 2020
- Immune Checkpoint Inhibitor Therapy–related Pneumonitis: Patterns and ManagementRadioGraphics, 2019
- Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non–Small-Cell Lung Cancer Who Received Programmed Death 1 InhibitorsClinical Lung Cancer, 2019
- 免疫检查点抑制剂相关肺炎的临床诊治建议2019
- Rapid temporal improvement of pembrolizumab-induced pneumonitis using the anti-TNF-α antibody infliximabDrug Discoveries & Therapeutics, 2019
- Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint ImmunotherapyJournal of Thoracic Oncology, 2019
- Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-AnalysisFrontiers in Immunology, 2019
- Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockadeJournal of Oncology Pharmacy Practice, 2017
- Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary FibrosisAnnual Review of Medicine, 2016
- Immune Checkpoint Inhibitors2015